血脂康联合他汀类药物对原发性高脂血症患者脂代谢及血管内皮功能的影响  

Effect of Xuezhikang Combined with Statins on Lipid Metabolism and Vascular Endothelial Function in Patients with Primary Hyperlipidemia

作　　者：牟蕾 林君健 MU Lei;LIN Jun-jian(Department of Pharmacy,Rizhao Downtown Hospital,Rizhao Shandong 276800,China;Department of Neurology,Rizhao Downtown Hospital,Rizhao Shandong 276800,China)

机构地区：[1]日照市中心医院药剂科,山东日照276800 [2]日照市中心医院神经内科,山东日照276800

出　　处：《中华养生保健》2023年第21期16-19,23,共5页CHINESE HEALTH CARE

摘　　要：目的探讨血脂康联合他汀类药物治疗原发性高脂血症的临床效果、对患者脂代谢及血管内皮功能的影响。方法回顾性分析2021年8月—2022年8月日照市中心医院收治的72例原发性高脂血症患者的临床资料,按用药方式不同,将接受阿托伐他汀治疗的36例患者设为对照组,接受血脂康联合阿托伐他汀治疗的36例患者设为观察组。比较两组治疗效果及不良反应发生情况。结果观察组总有效率高于对照组,差异有统计学意义(P<0.05)。观察组治疗后总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)水平低于对照组,高密度脂蛋白胆固醇(HDL-C)水平高于对照组,差异有统计学意义(P<0.05)。观察组治疗后一氧化氮(NO)水平高于对照组,内皮素(ET)水平低于对照组,差异有统计学意义(P<0.05)。观察组治疗后肿瘤坏死因子-α(TNF-α)、C反应蛋白(CRP)水平低于对照组,差异有统计学意义(P<0.05)。观察组治疗后丙二醛(MDA)水平低于对照组,谷胱甘肽过氧化物酶(GSH-Px)、超氧化物岐化酶(SOD)水平高于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论血脂康联合他汀类药物可提高原发性高脂血症治疗效果,纠正血脂紊乱,减轻炎症及氧化应激反应,安全可靠。Objective To investigate the clinical effect of combined treatment with Xuezhikang and statins in the treatment of primary hyperlipidemia and the effect on lipid metabolism and vascular endothelial function.Methods Clinical data of 72 patients with primary hyperlipidemia admitted to Rizhao Central Hospital from August 2021 to August 2022 were retrospectively analyzed.According to different medication methods,36 cases receiving atorvastatin treatment were set as control group,and 36 cases receiving Xuezhikang combined with atorvastatin treatment were set as observation group.The clinical efficacy,lipid metabolism indexes,vascular endothelial function,inflammation levels,oxidative stress indexes and adverse reactions were compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group,the levels of total cholesterol(TC),triglyceride(TG)and low density lipoprotein cholesterol(LDL-C)were lower than those of the control group,and the level of high density lipoprotein cholesterol(HDL-C)was higher than that of the control group after treatment(P<0.05).After treatment,nitric oxide(NO)level was higher than that of control group,endothelin(ET)level was lower than that of control group,and there were statistical differences(P<0.05).The levels of CRP,IL-6 and TNF-αin observation group were lower than those in control group after treatment,and there were statistical differences(P<0.05).After treatment,the malondialdehyde(MDA)level in observation group was lower than that in control group,while the glutathione peroxidase(GSH-Px),superoxide dismutase(SOD)and total antioxidant capacity(TAOP)levels in observation group were higher than those in control group,with statistical difference(P<0.05).There was no significant difference in adverse reactions between the two groups(P>0.05).Conclusion Xuezhikang combined with statins can improve the treatment effect of primary hyperlipidemia,correct lipid disorders,reduce inflammation and oxidative stress reaction,protect

关 键 词：原发性高脂血症 血脂康 阿托伐他汀 脂代谢 血管内皮功能 

分 类 号：R972[医药卫生—药品]